Literature DB >> 9006341

Resistance to cerebral malaria in tumor necrosis factor-alpha/beta-deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response.

W Rudin1, H P Eugster, G Bordmann, J Bonato, M Müller, M Yamage, B Ryffel.   

Abstract

Tumor necrosis factor (TNF) induced by Plasmodium berghei ANKA (PbA) infection was suggested to play an important role in the development of cerebral malaria (CM). We asked whether TNF-alpha/beta double-deficient mice, which have a complete disruption of the TNF-signaling pathways, are protected from CM and what might be the possible mechanisms of protection. PbA infection induces fatal CM in wild-type mice, which die within 5 to 8 days with severe neurological signs. In contrast, TNF-alpha/beta-deficient mice are completely resistant to PbA-induced CM. As PbA-induced up-regulation of endothelial intercellular adhesion molecule (ICAM)-1 expression as well as the systemic release of nitric oxide is found only in wild-type mice, TNF is apparently central for the recruitment of mononuclear cells and microvascular damage. Mononuclear cell adhesion to the endothelium, vascular leak and, perivascular hemorrhage are found only in the brain of wild-type mice. By contrast, the development of parasitemia and anemia is independent of TNF. Resistance to CM in TNF-alpha/beta-deficient mice is associated with reduced interferon-gamma and interleukin-12 expression in the brain, in the absence of increased T helper type 2 cytokines. In conclusion, TNF apparently is required for PbA-induced endothelial ICAM-1 up-regulation and subsequent microvascular pathology resulting in fatal CM. In the absence of TNF, ICAM-1 and nitric oxide up-regulation are reduced, and PbA infection fails to cause fatal CM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9006341      PMCID: PMC1858518     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Effect of blood transfusion on survival among children in a Kenyan hospital.

Authors:  E M Lackritz; C C Campbell; T K Ruebush; A W Hightower; W Wakube; R W Steketee; J B Were
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

2.  L3T4+ T lymphocytes play a major role in the pathogenesis of murine cerebral malaria.

Authors:  G E Grau; P F Piguet; H D Engers; J A Louis; P Vassalli; P H Lambert
Journal:  J Immunol       Date:  1986-10-01       Impact factor: 5.422

3.  An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration.

Authors:  G D Turner; H Morrison; M Jones; T M Davis; S Looareesuwan; I D Buley; K C Gatter; C I Newbold; S Pukritayakamee; B Nagachinta
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

4.  Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor.

Authors:  G E Grau; H Heremans; P F Piguet; P Pointaire; P H Lambert; A Billiau; P Vassalli
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

5.  Transgenic mice expressing high levels of soluble TNF-R1 fusion protein are protected from lethal septic shock and cerebral malaria, and are highly sensitive to Listeria monocytogenes and Leishmania major infections.

Authors:  I Garcia; Y Miyazaki; K Araki; M Araki; R Lucas; G E Grau; G Milon; Y Belkaid; C Montixi; W Lesslauer
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

6.  IL-12-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism.

Authors:  M M Stevenson; M F Tam; S F Wolf; A Sher
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

7.  Lymphotoxin-alpha-deficient mice. Effects on secondary lymphoid organ development and humoral immune responsiveness.

Authors:  T A Banks; B T Rouse; M K Kerley; P J Blair; V L Godfrey; N A Kuklin; D M Bouley; J Thomas; S Kanangat; M L Mucenski
Journal:  J Immunol       Date:  1995-08-15       Impact factor: 5.422

8.  Production of interleukin-6 by human and murine mononuclear leukocytes stimulated with Plasmodium antigens is enhanced by pentoxifylline, and tumor necrosis factor secretion is reduced.

Authors:  J Prada; C Prager; S Neifer; U Bienzle; P G Kremsner
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

Review 9.  Malaria pathogenesis.

Authors:  L H Miller; M F Good; G Milon
Journal:  Science       Date:  1994-06-24       Impact factor: 47.728

10.  In vivo sequestration of Plasmodium falciparum-infected human erythrocytes: a severe combined immunodeficiency mouse model for cerebral malaria.

Authors:  K Willimann; H Matile; N A Weiss; B A Imhof
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more
  38 in total

1.  Genetic susceptibility to systemic lupus erythematosus protects against cerebral malaria in mice.

Authors:  Michael Waisberg; Tatyana Tarasenko; Brandi K Vickers; Bethany L Scott; Lisa C Willcocks; Alvaro Molina-Cruz; Matthew A Pierce; Chiung-yu Huang; Fernando J Torres-Velez; Kenneth G C Smith; Carolina Barillas-Mury; Louis H Miller; Susan K Pierce; Silvia Bolland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  TLR9 polymorphisms are associated with altered IFN-gamma levels in children with cerebral malaria.

Authors:  Nadia A Sam-Agudu; Jennifer A Greene; Robert O Opoka; James W Kazura; Michael J Boivin; Peter A Zimmerman; Melissa A Riedesel; Tracy L Bergemann; Lisa A Schimmenti; Chandy C John
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

3.  Protein kinase C-theta is required for development of experimental cerebral malaria.

Authors:  Mathilde Fauconnier; Marie-Laure Bourigault; Sandra Meme; Frederic Szeremeta; Jennifer Palomo; Adeline Danneels; Sabine Charron; Lizette Fick; Muazzam Jacobs; Jean-Claude Beloeil; Bernhard Ryffel; Valerie F J Quesniaux
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

4.  Depletion of Phagocytic Cells during Nonlethal Plasmodium yoelii Infection Causes Severe Malaria Characterized by Acute Renal Failure in Mice.

Authors:  Mohamad Alaa Terkawi; Maki Nishimura; Hidefumi Furuoka; Yoshifumi Nishikawa
Journal:  Infect Immun       Date:  2016-01-11       Impact factor: 3.441

5.  Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice.

Authors:  P F Piguet; C Da Laperrousaz; C Vesin; F Tacchini-Cottier; G Senaldi; G E Grau
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 6.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

7.  Cloned lines of Plasmodium berghei ANKA differ in their abilities to induce experimental cerebral malaria.

Authors:  V Amani; M I Boubou; S Pied; M Marussig; D Walliker; D Mazier; L Rénia
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

8.  Evidence for multiple pathologic and protective mechanisms of murine cerebral malaria.

Authors:  V M Jennings; A A Lal; R L Hunter
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Regulation of proinflammatory cytokine expression in primary mouse astrocytes by coronavirus infection.

Authors:  Dongdong Yu; Hongqing Zhu; Yin Liu; Jianzhong Cao; Xuming Zhang
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

10.  Murine cerebral malaria development is independent of toll-like receptor signaling.

Authors:  Dieudonnée Togbe; Louis Schofield; Georges E Grau; Bruno Schnyder; Victorine Boissay; Sabine Charron; Stéphanie Rose; Bruce Beutler; Valérie F J Quesniaux; Bernhard Ryffel
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.